Axiom Bio is a Florida-based biotechnology startup developing next-generation diagnostic and rescue therapies for opioid overdose. Founded in 2025, we are currently advancing our lead candidate, AXM-OX, through preclinical development with a functional prototype, pending IP, and early-stage capital secured.

AXM-OX is a dual-action intranasal formulation combining naloxone with oxytocin, designed to reverse opioid overdose while reducing the psychological distress and trauma that often follow. By targeting both the acute physiological crisis and the emotional aftermath, AXM-OX offers a novel approach to stabilization and relapse prevention.

Our proprietary formulation is supported by early in vitro data and is preparing for GLP-compliant testing. We are finalizing lab partnerships, scaling up material synthesis, and actively engaging with investors, CROs, and academic collaborators to accelerate development.

Based in Gainesville, FL, Axiom Bio is proudly led by first-generation founders committed to science-driven design and public health innovation. Our mission is simple: transform overdose reversal from a moment of survival into the start of recovery.